(lp0
S"Here's What Hurt Inovio Pharmaceuticals Inc. Stock Today Motley Fool - Mar 16, 2017 Shares of DNA-based vaccine pioneer Inovio Pharmaceuticals Inc.  are under the weather after the company reported fourth-quarter and full-year earnings.Inovio Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 17 - Equities.comInovio Pharmaceuticals'  CEO J. Joseph Kim on Q4 2016 Results - Earnings ... - Seeking Alpha"
p1
aS'How Risky Is Inovio Pharmaceuticals, Inc.? Motley Fool - Jan 5, 2017 Last year was extremely eventful for Inovio Pharmaceuticals, Inc.  as it made headlines with a Zika virus candidate and suffered a regulatory setback.'
p2
aS"The Potential and Peril with Inovio Pharmaceuticals, Inc. Motley Fool - Nov 12, 2016 Cory also correctly noted that Inovio finished mid-stage testing of its experimental cervical dysplasia vaccine VGX-3100 over two years ago and still hadn't begun enrolling for the planned late-stage study when the U.S.HC Wainwright Cuts Price Target For Inovio Pharmaceuticals Inc , But ... - Smarter AnalystInovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain ... - GlobeNewswire "
p3
aS'Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax Motley Fool - Oct 25, 2016 Novavax  shareholders can attest to that, while Inovio Pharmaceuticals  investors hope to enjoy a smoother ride.HC Wainwright Remains Bullish on Inovio Pharmaceuticals Inc  Despite FDA ... - Smarter Analyst'
p4
aS"Inovio Pharmaceuticals, Inc. in 3 Charts Motley Fool - Sep 13, 2016 Shareholders of Inovio Pharmaceuticals  didn't have much to smile about in 2014 and 2015. This year, however, is a much different story.Inovio's Zika Vaccine Bags Tech Award  - Investopedia"
p5
aS"Inovio Pharmaceuticals, Inc.'s Biggest Win in 2016 Motley Fool - Dec 9, 2016 If 2016 had stopped in June, it would have been a fantastic year for Inovio Pharmaceuticals . The biotech's stock shot up around 70% by mid-way through the year."
p6
aS"Here's Why Inovio Pharmaceuticals, Inc. Shares Tanked 30.6% in October Motley Fool - Nov 8, 2016 Last month, shares of clinical-stage DNA-based therapy developer Inovio Pharmaceuticals, Inc.  fell 30.6%, according to data from S&amp;P Global Market Intelligence.Inovio Pharmaceuticals'  CEO Joseph Kim on Q3 2016 Results - Earnings ... - Seeking AlphaInovio Pharmaceuticals Inc  Stock: Spiking On Positive Study Results - Insider Monkey "
p7
aS'Biogen, Inovio Pharmaceuticals, Rubicon Project Times of India - Mar 16, 2017 HIGHLIGHTS * Biogen Inc : Morgan Stanley cuts to equal-weight from overweight * Inovio Pharmaceuticals Inc : Piper Jaffray cuts to neutral from overweight * Oracle Corp : Deutsche Bank raises target price to $44 from $40; rating hold * Rubicon Project ...'
p8
aS'Maxim Weighs In on Inovio Pharmaceuticals Inc  Following Positive ... Smarter Analyst - Feb 23, 2017 Maxim analyst Jason McCarthy reiterated a Hold rating on shares of Inovio Pharmaceuticals Inc , after the vaccine maker presented positive clinical data for DNA-based vaccines targeting MERS  and Zika&nbsp;...Analyst Activity  HC Wainwright Reiterates Buy on Inovio Pharmaceuticals ... - Market ExclusiveInovio Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 23 - Equities.com'
p9
aS"Stock Update : Inovio Pharmaceuticals Inc and ApolloBio to ... Smarter Analyst - Feb 13, 2017 Inovio Pharmaceuticals, Inc.  announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation  with the exclusive right to develop and commercialize VGX-3100, Inovio's DNA&nbsp;...Inovio and ApolloBio to Collaborate on Development and Commercialization of ... - GlobeNewswire Inovio teams up with ApolloBio to develop VGX-3100 in China - Seeking Alpha"
p10
a.